Modus Therapeutics AB
Modus Therapeutics is a Swedish biotechnology company developing the drug candidate Sevuparin for the difficult-to-treat condition sepsis and septic shock. A condition which leads to around 11 million deaths each year from a global perspective.
-
Homepage:
www.modustx.com
-
Initial coverage:
In English
Contacts
Sector:
HealthcareIndustry:
PharmaceuticalsExchange:
Nasdaq First North GrowthTicker:
MODTX:SS
Analysis, Modus Therapeutics
2021-12-06 Mrkt BUZZ: Executing on an ambitious timeline
2021-11-08 Mrkt BUZZ: Benefiting from sepsis care initiative
2021-11-01 Initial coverage: Promising Phase I candidate in huge market
2021-07-09 Investment case: Significant potential with proven technology
Historical figures
Revenue (MSEK)